Trial Information

Official Title: A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Summary

This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of MABT5102A on brain amyloid burden (as assessed by amyloid PET imaging) and other biomarkers in patients with mild to moderate Alzheimer's disease.

Phase: Phase 2

Sponsor: Genentech

Overall Contacts:

Please reference Study ID Number: ABE4955g www.roche.com/about_roche/roche_worldwide.htm
888-662-6728 (U.S. Only)
genentechclinicaltrials@druginfo.com